449.45MMarket Cap-9363P/E (TTM)
2.0800High2.0300Low1.62MVolume2.0500Open2.0500Pre Close3.34MTurnover0.82%Turnover RatioLossP/E (Static)218.18MShares2.480052wk High-8.92P/B408.44MFloat Cap0.800052wk Low--Dividend TTM198.27MShs Float31.0000Historical High--Div YieldTTM2.44%Amplitude0.2410Historical Low2.0550Avg Price1Lot Size
Akebia Therapeutics Stock Forum
3 mins ago
Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization to Enable Access to Vafseo® (Vadadustat) for Patients on Dialysis! Expected to be available in USA in January 2025
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assig...
Akebia Therapeutics Inc - Contract Enables Prescription of Vafseo for Dialysis Patients From Jan 2025
No comment yet